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ORIGINAL ARTICLE
Comparison of the Utility and Validity of Three
Scoring Tools to Measure Skin Involvement
in Patients With Juvenile Dermatomyositis
RAQUEL CAMPANILHO-MARQUES,1 BEVERLEY ALMEIDA,1 CLAIRE DEAKIN,2 KATIE ARNOLD,2
NATACHA GALLOT,2 MARIA DE IORIO,2 KIRAN NISTALA,2 CLARISSA A. PILKINGTON,3 AND
LUCY R. WEDDERBURN,4 ON BEHALF OF THE JUVENILE DERMATOMYOSITIS RESEARCH GROUP
Objective. To compare the abbreviated Cutaneous Assessment Tool (CAT), Disease Activity Score (DAS), and Myositis
Intention to Treat Activity Index (MITAX) and correlate them with the physician’s 10-cm skin visual analog scale (VAS) in
order to define which tool best assesses skin disease in patients with juvenile dermatomyositis.
Methods. A total of 71 patients recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study were included
and assessed for skin disease using the CAT, DAS, MITAX, and skin VAS. The Childhood Myositis Assessment Scale
(CMAS), manual muscle testing of 8 groups (MMT8), muscle enzymes, inflammatory markers, and physician’s global VAS
were recorded. Relationships were evaluated using Spearman’s correlations and predictors with linear regression.
Interrater reliability was assessed using intraclass correlation coefficients.
Results. All 3 tools showed correlation with the physician’s global VAS and skin VAS, with DAS skin showing the strongest
correlation with skin VAS. DAS skin and CAT activity were inversely correlated with CMAS and MMT8, but these correla-
tions were moderate. No correlations were found between the skin tools and inflammatory markers or muscle enzymes. DAS
skin and CAT were the quickest to complete (mean6SD 0.6860.1 minutes and 0.636 0.1 minutes, respectively).
Conclusion. The 3 skin tools were quick and easy to use. The DAS skin correlated best with the skin VAS. The addi-
tion of CAT in a bivariate model containing the physician’s global VAS was a statistically significant estimator of skin
VAS score. We propose that there is scope for a new skin tool to be devised and tested, which takes into account the
strengths of the 3 existing tools.
INTRODUCTION
Juvenile dermatomyositis (DM) is a rare inflammatory dis-
ease of childhood that predominantly affects muscles and
skin but is also a systemic multiorgan disease (1). It is the
most common idiopathic inflammatory myopathy (IIM) of
childhood, with a reported incidence of 2–3 new cases per
million children per year (2). Juvenile DM is clinically
heterogeneous, with some children experiencing mild dis-
ease while others display a more severe disease progression.
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Skin manifestations include Gottron’s papules, erythema,
heliotrope rash, ulceration, lipodystrophy, and calcinosis
(3). Within the UK Juvenile Dermatomyositis Cohort and
Biomarker Study, 88% of patients with juvenile DM have
rash, 23% have skin ulceration, and 7% have calcinosis (4).
Children can show severe myositis with or without skin dis-
ease, or with skin disease as the predominant feature and
mild myositis. This variation poses a problem, since skin
disease can be difficult to control and is less responsive to
standard treatment than muscle disease. Evidence suggests
that poorly controlled skin disease is a predictor of severity
and damage (5). An accurate assessment of skin involve-
ment is of critical importance in determining clinical status,
making treatment decisions, and predicting outcome in
juvenile DM.
In clinical practice, muscle symptoms of juvenile DM are
frequently the main initial focus. Formal measures such as the
Childhood Myositis Assessment Scale (CMAS) (6) and man-
ual muscle testing of 8 groups (MMT8) (7) exist to standardize
the muscle assessment. Both are part of the agreed Juvenile
Dermatomyositis Paediatric Rheumatology International
Trials Organisation (8) and International Myositis Assessment
and Clinical Studies Group (9) core disease activity measures.
Despite the importance of skin disease, at present many physi-
cians and other health care professionals who care for chil-
dren with juvenile DM do not routinely measure the severity
of skin activity using a validated tool. Several tools have been
proposed to measure skin disease in juvenile DM. These
include the abbreviated Cutaneous Assessment Tool (CAT),
encompassing active skin disease and skin damage (10), the
Disease Activity Score (DAS) (11), and the Myositis Intention
to Treat Activity Index (MITAX) (12). The latter 2 tools both
have skin components (although they are not skin specific).
Only 3 specific items are in all 3 tools (Gottron’s papules,
heliotrope rash, and periungual capillary changes). The
MITAX was designed to assess all organ systems likely to
be involved in IIMs and is not specific to skin alone. The
MITAX does not include some cutaneous clinical features
such as calcinosis and lipoatrophy, which are felt to be
severe skin manifestations by many physicians. It consists
of a relatively long form with a complex scoring system
that then requires conversion to a categorical scale. The reli-
ability of the MITAX has been found to be fair to good for
most aspects of the tool in initial testing (12). The DAS has
good reliability and validity (11). Like the MITAX, it was not
solely designed to test the skin alone. It is easy to use, but
the weighting of the items is relatively arbitrary. It also does
not take into account the severity or different forms of some
signs, such as different types of vasculitic changes, and does
not consider several items, including calcinosis, lipoatro-
phy, shawl sign, V sign, mechanic’s hands, or ulceration.
The abbreviated CAT score has been shown to have consis-
tency, nonredundancy, and good construct validity (10). It
was designed specifically to assess skin disease in juvenile
DM. This tool is the easiest to use (items are scored dichoto-
mously: the indicator is present or not), and it is the tool that
considers the most skin features. The following items
that are scored in the CAT are not included in the other
2 tools: linear extensor erythema, shawl sign, V sign, non-
sun exposed erythema, livedo reticularis, cuticular over-
growth, subcutaneous edema, calcinosis, and lipoatrophy.
However, it gives equal weighting to all skin signs, whereas
in clinical practice many physicians may deem some signs,
such as ulceration to be more important than, for example,
livedo reticularis, or hypopigmented Gottron’s papules. In
addition, the CAT does not consider the distribution of skin
involvement.
However the optimal tool is unknown. The goal of this
study was to directly compare these 3 tools and evaluate
the measurement characteristics of the CAT, DAS, and
MITAX, including construct validity, interrater reliability,
and their ability to detect skin disease activity in a large
cohort of children and young people with juvenile DM, in
order to define which existing tool best assesses skin dis-
ease in juvenile DM.
PATIENTS AND METHODS
Patients and measures. A total of 71 patients were
recruited via the UK Juvenile Dermatomyositis Cohort and
Biomarker Study. All met the Bohan and Peter classification
criteria (13,14) for definite or probable juvenile DM and
were ages ,16 years at the time of diagnosis. At clinical
assessment, a structured history and physical examination
were obtained. A complete skin assessment was performed
by 2 pediatric rheumatologists (RC-M, BA), both trained by
specialists with expertise in juvenile DM in a tertiary pediat-
ric rheumatology center. Each patient was assessed for skin
disease using the abbreviated CAT, DAS, MITAX, and an
overall 0–10-cm physician’s skin visual analog scale (VAS),
considering both activity and damage. A subset of patients
(n520) was assessed at 2 time points, at a mean6SD time
of 5.526 7.08 months apart. The abbreviated CAT binary
method uses 21 items, subdividing skin involvement into
active disease and disease damage lesions, with 17 items in
the active section and 11 in the damage section. Each lesion
receives a score of 1 if present and 0 if absent (10). Higher
scores indicate greater skin disease activity. The DAS is a
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20-point scale, with 2 subsections, 1 assessing skin disease
(range 0–9) and the second assessing muscle inflammation
(range 0–11). Higher scores indicate greater disease activity
(11). The MITAX (12) was developed along similar lines to
the British Isles Lupus Assessment Group score, used to
assess disease activity in patients with lupus. The scoring
system is based on the physician’s intention to treat. The
MITAX assesses the following organ systems: constitu-
tional, cutaneous, skeletal, gastrointestinal, pulmonary, car-
diac, and musculoskeletal. Each item is scored between 0
and 4 (based on the presence of clinical features at the time
or symptoms within the previous 4 weeks). For each of the
organ system sections, the scale is categorical, with scores of
0, 1, 3, or 9. For the DAS and MITAX, both tools were scored
in their entirety. For the purposes of this study the skin sec-
tion was the area of interest for both these tools.
Core outcome variables for juvenile DM were collected,
including CMAS (6), MMT8 (7), the physician’s global
assessment of overall disease activity (using a 0–10-cm
VAS), serum levels of muscle-associated enzymes (crea-
tine kinase [CK; units/liter], aspartate aminotransferase
[AST; units/liter], alanine transaminase [ALT; units/liter]
and lactate dehydrogenase [LDH; units/liter]) and inflam-
matory markers (C-reactive protein level [CRP; mg/liter]
and erythrocyte sedimentation rate [ESR; mm/hour]).
Statistical analysis. Nonparametric and parametric sum-
mary statistics were used to describe the distribution of
score data for each tool. Validity was assessed by comparing
the tools with the skin VAS as a means of identifying
whether they were clinically and accurately reflecting cur-
rent skin disease states. Construct validity determines
whether a variable (or set of variables), in this case the skin
tools, is related to other measures and do indeed measure
skin disease. As there is no accepted gold standard for
assessing skin disease in juvenile DM, the skin VAS was
used to test whether the 3 outcome skin tools accurately
reflected their purported outcome measurements. Construct
validity also examines the relationships between the tools
and measures of other constructs, such as laboratory results
and muscle testing (CMAS and MMT8). The nonparametric
Spearman’s rank correlation (rs) was selected for analysis of
correlation between each score tool and skin VAS, since the
distributions of scores generated using these tools were not
normal and also because the MITAX skin score is not mea-
sured on a linear scale. For the purpose of this analysis, cor-
relations $0.75 (and conversely#2 0.75) were considered
strong, correlations ranging from 0.40 to 0.75 (and con-
versely2 0.4 to20.75) were considered moderate, and cor-
relations ,0.4 (and conversely.20.4) were considered
poor. To correct for multiple comparisons, a 2-sided P value
less than 0.001 was considered statistically significant.
The relative ability of the skin tools to predict skin VAS
was assessed by linear regression modelling. Univariate
models were compared by considering the proportion of
variance in skin VAS explained by the model, as esti-
mated by the adjusted model R2. Bivariate models were
used to assess which combinations of measures contrib-
uted the most to explain the variance in skin VAS.
Bivariate models were compared to their respective nested
univariate models using analysis of variance (ANOVA).
The variance inflation factor (VIF) was calculated to
detect possible multicollinearity between variables in the
bivariate models. For patients whose skin disease was
assessed at multiple time points, sensitivity of each tool to
measure change over time was estimated by calculating
the standardized response mean (SRM). The SRM repre-
sents the mean of the differences in the tools between time
points, divided by the SD of those differences. The SRM
was calculated for the tools that are measured on a linear
scale (skin VAS, DAS skin, and CAT activity). Absolute
numbers were used for the ranges. Cohen’s thresholds (15)
(trivial ,0.20, small $0.20 to ,0.50, moderate $0.50 to
,0.80, or large $0.80) were used for grading the SRM
values.
To assess interrater reliability, 18 of the 71 patients were
assessed by the 2 pediatric rheumatologists on the same
day; each was unaware of the other’s scores. Agreement
intraclass correlation coefficients were calculated for the
overall score of each tool to assess how consistent the scores
were between the 2 physicians. This calculation was per-
formed using a 2-way model to account for the variability
attributable to observers in addition to the variability attrib-
utable to the subjects. A value.0.75 was indicative of excel-
lent agreement and between 0.4 and 0.75 was considered fair
to good agreement (16). There was no disagreement between
the physicians. Analyses were performed using R software,
version 3.0.1. As multiple tests were used, 2-sided P values
less than 0.001 were considered to be statistically significant.
RESULTS
Patients and outcome measures. Of the 71 patients
assessed, 59.2% were female and 71.8% were white. At
the time of assessment the mean6SD age was 9.863.8
years. The mean6SD age at diagnosis was 6.663.4 years,
at assessment 9.863.8 years, and duration at time of
Table 1. Demographic data of all patients*
Variables
Juvenile DM
(n571)
Demographics
Female 42 (59)
White 51 (72)
Age, mean6SD years 9.86 3.8
Age at diagnosis, mean6SD years 6.06 3.4
Disease duration, mean6SD years 3.363
Treatment at time of assessment
PDN alone 2 (3)
MTX alone 20 (28.2)
MTX1PDN alone 20 (28.2)
AZA1PDN alone 5 (7)
MTX1 IvIg alone 4 (5.6)
MTX1CYC alone 4 (5.6)
MTX1 IvIg1CYC 4 (5.6)
Steroids1MTX1AZA 4 (5.6)
Biologic agents with other DMARDs 8 (11.2)
* Values are the number (%) unless indicated otherwise. DM5 derma-
tomyositis; PDN5prednisolone; MTX5methotrexate; AZA5 azathio-
prine; IvIg5 intravenous immunoglobulin; CYC5 cyclophosphamide;
DMARDs5disease-modifying antirheumatic drugs.
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assessment 3.36 3.0 years (Table 1). Our cohort had simi-
lar demographics to previously described cohorts (2) and
is representative of juvenile DM patients. The disease
activity measures at the time of assessment are shown in
Table 2. The median skin VAS score at assessment was 1.5
(interquartile range 0.2–3.5). The median scores for the
tools erred towards minimal to moderate evidence of skin
disease. (Figure 1). The CMAS and MMT8 score medians
demonstrated inactive or minimal muscle disease at the
time of assessment.
Construct validity. Spearman’s correlation coefficients
were used to assess construct validity of the skin tools by
correlating each tool with either the skin VAS or physician’s
global VAS (Table 3). All skin assessment tools correlated
positively with both the physician’s global VAS and skin
VAS. The CAT and the skin sections of both the DAS
and MITAX correlated well with the skin VAS (rs5 0.63,
P, 0.001; rs5 0.79, P, 0.001; and rs5 0.60, P, 0.001,
respectively) (Figure 2). The skin section of the DAS had a
statistically higher correlation with the skin VAS than the
other 2 tools. For the physician’s global VAS, the correlation
coefficient was strongest (rs. 0.75) between physician’s
global VAS/total MITAX and physician’s global VAS/total
DAS, as all of these perform a generalized assessment of the
disease.
The relationship between the tools and muscle disease
measures and inflammatory markers was investigated
(Table 3). DAS skin and CAT activity scores were both
moderately inversely correlated with both CMAS and
MMT8 scores. Inverse correlations were expected, given
that muscle scores are low in severe weakness, while skin
scores are high in the presence of high skin disease activity.
However, this correlation was only moderate, reflecting the
fact that skin disease can be active after myositis resolves
and vice versa. MITAX skin was also inversely correlated
with the MMT8 score, but no significant correlation was
observed with the CMAS. There were no significant
Figure 1. Frequency of skin scores in the 71 patients according to the skin
tools. The panels show the scores for A, skin visual analog scale (VAS),
B, Disease Activity Score (DAS) skin, C, Myositis Intention to Treat Activity
Index (MITAX) skin, and D, Cutaneous Assessment Tool (CAT) activity.
Each symbol represents a patient; horizontal lines represent the median.
Table 2. Descriptive statistics of tools and disease
activity measures*
Variables No. Median (IQR)
Tools
CAT activity (range 0–17) 71 2 (0–4)
CAT damage (range 0–11) 71 0 (0–1)
DAS total (range 0–20) 71 5 (2–8)
DAS skin (range 0–9) 71 4 (1–5)
MITAX total (range 0–63) 71 3 (1–7)
MITAX skin (range 0–9) 71 3 (1–3)
Physician’s evaluations
Global VAS (range 0–10) 71 2.0 (0.1–4.0)
Skin VAS (range 0–10) 71 1.5 (0.2–3.5)
Muscle disease measures
CMAS (range 0–53) 71 50 (46–53)
MMT8 (range 0–80) 71 80 (69–80)
CK (normal ,150 units/liter) 55 89 (68–161)
Inflammatory markers
CRP (normal ,20 mg/liter) 57 5 (5–5)
ESR (normal ,10 mm/hour) 55 9 (4–16)
* IQR5 interquartile range; CAT5Cutaneous Assessment Tool;
DAS5Disease Activity Score; MITAX5Myositis Intention to Treat
Activity Index; VAS5visual analog scale; CMAS5Childhood Myositis
Assessment Scale; MMT85manual muscle testing in 8 groups;
CK5 creatine kinase; CRP5C-reactive protein; ESR5 erythrocyte sedi-
mentation rate.
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correlations between the muscle enzymes CK, ALT, AST,
or LDH and any of the tools or their skin subsections. No
significant correlations were found between the skin tools
and inflammatory markers.
Estimation of disease activity. Having found that skin
VAS correlated most strongly with each of the other tools,
we next evaluated the capacity of each tool to predict skin
VAS. Results of univariate and bivariate regression analy-
ses to investigate the ability of the skin tools to accurately
estimate skin disease activity, as measured by skin VAS,
are summarized in Table 4. In univariate models, although
all the measures were significant skin disease activity
determinants, the skin sections of the tools were stronger
than the global tools. The DAS skin appeared to be the stron-
gest tool to evaluate skin VAS, based on having the highest
model-adjusted R2, therefore accounting for the greatest
degree of variance in skin VAS.
In the bivariate models of skin VAS, the addition of the
physician’s global VAS to the tools CAT activity, DAS total,
DAS skin, MITAX global, and MITAX skin strengthened
each of those models, as revealed by the ANOVA compari-
sons of the bivariate models to their respective nested
univariate models (Table 4). Both variables in the bivariate
model consisting of CAT activity and physician’s global
VAS were statistically significant, accounting for a propor-
tion of variance in skin VAS of R250.422. Although the
bivariate model using the combination of DAS skin and phy-
sician’s global VAS appeared to be a stronger estimator of
skin VAS (R25 0.557), the physician’s global VAS was not
statistically significant in this model (P5 0.012), using the
stringent threshold of 0.001 (to allow for multiple compari-
sons). VIF values for each of the bivariate models indicated
that multicollinearity was not likely to have affected the pre-
cision of the estimates.
For the 20 patients who were assessed at 2 separate time
points, the SRM value for skin VAS, DAS skin, and CAT
was 1.18, 0.55, and 0.15, respectively. Skin VAS displayed
the greatest magnitude of change over time, skin DAS was
moderate, and CAT was trivial. The intraclass correlation
coefficients were all above 0.75, indicating excellent inter-
rater reliability between the 2 physicians.
Time for instrument completion. Physicians individu-
ally kept track of their time to complete (i.e., to fill out the
form and obtain a score) the skin section of each tool
Table 3. Correlation between the tools and other disease activity measures using Spearman’s correlation
with corresponding P value*
CAT activity CAT damage DAS total DAS skin MITAX total MITAX skin
Disease activity
measures Values P Values P Values P Values P Values P Values P
Physician’s evaluations
Skin VAS (n5 71) 0.63 , 0.001 0.34 0.004 0.74 , 0.001 0.79 , 0.001 0.60 , 0.001 0.60 , 0.001
Global VAS (n5 71) 0.59 , 0.001 0.19 0.11 0.78 , 0.001 0.68 , 0.001 0.79 , 0.001 0.67 , 0.001
Muscle disease measures
CMAS (n5 71) 20.42 , 0.001 0.2 0.1 20.63 , 0.001 20.42 , 0.001 20.55 , 0.001 20.35 0.003
MMT8 (n571) 20.39 0.001 0.16 0.18 20.66 , 0.001 20.4 , 0.001 20.6 , 0.001 20.41 , 0.001
CK (n5 55) 0.13 0.33 20.04 0.79 0.27 0.05 0.2 0.14 0.2 0.13 0.13 0.33
ALT (n553) 20.09 0.46 0.02 0.88 0.01 0.96 0.02 0.88 20.06 0.6 0.06 0.63
AST (n527) 0.09 0.46 20.1 0.38 0.2 0.1 0.18 0.14 0.14 0.26 0.13 0.29
LDH (n5 48) 0.07 0.57 0.02 0.88 0.12 0.32 0.15 0.21 0.02 0.87 0.15 0.21
Inflammatory markers
CRP (n5 57) 0.28 0.03 0.02 0.87 0.34 0.01 0.3 0.02 0.26 , 0.001 0.18 0.19
ESR (n5 55) 0.16 0.24 20.11 0.94 0.36 0.01 0.32 0.02 0.38 0.005 0.28 0.04
* CAT5Cutaneous Assessment Tool; DAS5Disease Activity Score; MITAX5Myositis Intention to Treat Activity Index; VAS5 visual analog
scale; CMAS5Childhood Myositis Assessment Scale; MMT85manual muscle testing in 8 groups; CK5 creatine kinase; ALT5 alanine transami-
nase; AST5 aspartate aminotransferase; LDH5 lactate dehydrogenase; CRP5C-reactive protein; ESR5 erythrocyte sedimentation rate.
Figure 2. Analysis of relationships between skin visual analog scale (VAS) and skin tool scores.
A, Cutaneous Assessment Tool (CAT) activity score, B, Disease Activity Score (DAS) skin, and C, Myositis
Intention to Treat Activity Index (MITAX) skin score, with superimposed regression lines.
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(MITAX, DAS, and CAT). The mean6SD times to com-
plete the forms for the MITAX skin, DAS skin, and CAT
were 1.460.24 minutes, 0.686 0.1 minutes, and 0.6360.1
minutes respectively (n5 33 patients).
DISCUSSION
Muscle disease is often the dominant clinical feature of juve-
nile DM. However, cutaneous involvement is a defining fea-
ture of juvenile DM and is an equally important
manifestation of both disease activity and disease damage
(17) as a source of morbidity and association with poorer
outcomes (18,19). For these reasons, skin disease activity
and damage are essential components of the overall assess-
ment of children with juvenile DM.
In this study we compared the 3 scoring tools to assess
skin in juvenile DM patients. The CAT and both the skin
sections of DAS and MITAX correlate well with the skin
VAS. All 3 tools had moderate correlation with the physi-
cian’s global VAS. Correlation with CK, ALT, AST, or
LDH was not found. In addition, no significant correla-
tions were found between the skin tools and the inflamma-
tory markers, CRP level and ESR. The global MITAX and
global DAS (2 tools that assess the skin as part of a general-
ized activity tool) had a higher correlation with the physi-
cian’s global VAS than the skin VAS.
When linear regression models were used to estimate skin
disease activity, the DAS skin, MITAX skin, and CAT activ-
ity were all significant estimators of skin disease activity.
The addition of CAT activity in a bivariate disease estimator
model containing the physician’s global VAS was a statisti-
cally significant estimator of skin VAS score. This finding
suggests that CAT activity provides additional information
to the physician’s global VAS, contributing to the assessment
of skin disease activity. According to Cohen’s threshold (15),
the skin VAS showed the largest responsiveness to change.
Although the other tools had lower SRM values, indicating
less sensitivity to change, they were still highly correlated
with skin VAS.
To our knowledge our study is the first of its kind among
patients in a juvenile dermatomyositis population. A previ-
ous study compared 3 skin-specific tools, the Cutaneous
Dermatomyositis Disease Area and Severity Index (CDASI),
the Dermatomyositis Skin Severity Index, and the CAT (20).
In that study, 10 dermatologists used these instruments to
score the same 12–16 adult patients with DM in 1 session.
The overall disease activity at the time of the study was
defined by the dermatologists completing a global physician
score, while the patients completed a global patient score and
global itch score. The CDASI was found to be a useful out-
come measure for studies of cutaneous DM. However, these
tools have not yet been validated in a pediatric population.
The disease course differs from adults, as do the skin disease
manifestations. Despite these differences, it would be inter-
esting to test the use of the CDASI in pediatric patients in a
future study.
One limitation of this study is that relatively few patients
had very active skin disease; most had mild to moderate
skin disease. This finding is likely to reflect the spectrum
seen in most rheumatology services. However, since 61% of
patients had a DAS skin score .4 (maximum score 9), we
believe that the population had enough skin disease to allow
testing of the tools. Another limitation of the study is that
currently there is no gold standard to assess skin disease in
juvenile DM. We found that both the physician’s global VAS
Table 4. Linear regression analyses of the ability of the tools to estimate physician skin
disease activity*
Predictor
variable
Standardized
parameter
estimate P
Model
adjusted R2 ANOVA (F) P VIF
Univariate
CAT activity 0.529 , 0.001 0.326 – – –
DAS total 0.268 , 0.001 0.335 – – –
DAS skin 0.633 , 0.001 0.521 – – –
MITAX global 0.124 , 0.001 0.148 – – –
MITAX skin 0.446 , 0.001 0.289 – – –
VAS global 0.492 , 0.001 0.318 – – –
Bivariate
CAT activity 0.354 , 0.001 0.422 12.205 , 0.001 1.36
VAS global 0.322 , 0.001
DAS total 0.165 0.01 0.370 4.732 0.03 2.19
VAS global 0.263 0.03
DAS skin 0.515 , 0.001 0.557 6.539 0.01 1.45
VAS global 0.210 0.012
MITAX total 0.064 0.230 0.323 18.775 , 0.001 3.04
VAS global 0.638 , 0.001
MITAX skin 0.275 0.003 0.392 12.58 , 0.001 1.40
VAS global 0.337 , 0.001
* ANOVA (F)5 analysis of variance bivariate model compared to nested univariate model;
VIF5variance inflation factor; CAT5Cutaneous Assessment Tool; DAS5Disease Activity Score;
MITAX5Myositis Intention to Treat Activity Index; VAS5visual analog scale.
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and the skin VAS correlated with all 3 tools, but the correla-
tions with the skin VAS were higher. In a recent study ana-
lyzing detailed data from a subgroup of patients in the
rituximab myositis trial, the physician’s skin VAS was
found to be sensitive to change in skin disease, with an SRM
of 1.1 (P,0.03) (21). We therefore chose to use the skin VAS
in our regression analyses, because although skin VAS and
overall VAS correlated well with each other (rs5 0.75,
P,0.0001, data not shown) skin VAS correlated better than
the physician’s global VAS with the other skin tools.
Skin disease can be active after the myositis has resolved,
and our own data demonstrate children with skin disease
yet relatively low overall VAS scores, and vice versa. The
routine and reliable measurement of skin activity in clini-
cal practice could influence treatment choices in juvenile
DM. Physicians should consider and document skin dis-
ease independently of muscle disease in the assessment
of children with juvenile DM. This study represents an
important step in the process of developing indicators to
monitor skin disease activity in children with juvenile DM.
The study results demonstrate that all 3 tools effectively
assess skin disease in children with juvenile DM. In a uni-
variate model the correlation was strongest between the
DAS skin and the physician’s skin VAS. In a bivariate
model, the addition of CAT to the physician’s global VAS
was the only one that maintained significance. However,
all 3 tools have limitations that must be taken into account.
The skin tools objectively capture items, but the weighting
of the items varies between tools. The skin VAS can cap-
ture items not in tools, allows physicians to apply their
own weighting, and allows skin activity to be assessed lon-
gitudinally in the clinic as well as for research. However,
we propose that the use of a skin VAS alone as a single tool
may miss important information, since individual skin fea-
tures would not be documented.
We therefore recognize that there is scope for a new skin
tool for juvenile DM that takes into account the strengths
of the 3 existing tools, to be devised, tested, and validated
in large cohorts using robust and internationally agreed
standards (22). Until that time we propose the use of a
skin VAS and one of these tools in routine practice could
improve recognition and prompt treatment of ongoing
skin disease in juvenile DM.
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